Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts

Zaharia, Oana‐Patricia; Lanzinger, Stefanie; Rosenbauer, Joachim; Karges, Wölfram; Müssig, Karsten; Meyhöfer, Sebastian M.; Burkart, Volker; Hummel, Michael; Roggenbuck, Dirk; Roden, Michael; Szendroedi, Julia; Holl, Reinhard W.

doi:10.3389/fendo.2022.760778

Cited by 2 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T1D predisposes to a number of comorbidities, such as obesity, chronic kidney disease, metabolic syndrome, coronary artery disease, and hypertension. Such predispositions may account for higher mortality rates, affecting up to one in 10 adult patients within a year of diagnosis [ 4 ]. In fact, diabetic nephropathy (DN) is said to account for up to 40% of end-stage renal disease (ESRD) cases worldwide.…”

Section: Introductionmentioning

confidence: 99%

The Role of Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes

Jayasinghe¹,

Prathiraja²,

Perera³

et al. 2022

Cureus

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is a chronic disease characterized by inadequate or absent insulin production due to the autoimmune destruction of beta (β) cells in the pancreas. It was once called "juvenile diabetes" since the disease frequently occurs in children, but it can also develop in adults. According to the International Diabetes Federation, an estimated 700 million adults will suffer from diabetes by 2045. Although the exact cause of diabetes remains unknown, it is hypothesized that genetic factors, environmental factors, and exposure to certain viruses play a role in the development of T1D. To date, exogenous insulin is the most common treatment for T1D. However, it is not a cure for the disease. Islet cell transplantation and pancreatic transplantation are two additional treatments that have gained popularity in recent years, but their clinical application may be limited by the need for high doses of immunosuppressants, the rarity of human cadaveric islets, and the need for extensive surgery in pancreatic transplantation. Mesenchymal stem cells (MSCs) are a highly promising novel treatment for T1D and their discovery has advanced biological sciences by allowing for modification of cell fate and the development of higher-order cellular structures. They play an essential role in lowering levels of fasting blood sugar, hemoglobin A1c, and C-peptide, and in treating microvascular complications associated with T1D. However, some of the disadvantages of its use in clinical practice are limited to its method of collection, proliferation rate, cell activity with age, and the risk of tumour formation identified in some studies. Large-scale studies are required to discover the mechanism of action of MSCs after administration as well as the optimal route, dose, and timing to maximize the benefits to patients. This article focuses primarily on the role of MSCs in the treatment of T1D and compares the feasibility, benefits, and drawbacks of MSCs in the treatment of T1D.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes

Jayasinghe¹,

Prathiraja²,

Perera³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

Evaluation of a Digital Health Application for Diabetics under real world conditions: Superior Outcomes Compared to Standard Care in a Matched Case-Control Study (Preprint)

Roth,

Wagner,

Riesner

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND Advanced technologies are key to enhancing diabetes care, improving patient outcomes and raising overall care quality. This is also reflected in their growing role in diabetes guidelines and countries like Germany, even offer the options of reimbursing costs for digital health apps. OBJECTIVE The present study aims to evaluate the effectiveness ESYSTA® (Emperra GmbH, Germany), a digital health application to support insulin-treated diabetes patients to improve their disease management through better self-empowerment. METHODS To evaluate the effectiveness of ESYSTA®, data from patients who used ESYSTA® for at least 12 months and participated in an originally prospective one-arm study, were evaluated. The study was conducted in cooperation with the German health insurance AOK Nordost (2012-2015). From a real-world data pool of insured AOK Nordost patients, a control group was matched to mimic a controlled trial that allows to compare the use of ESYSTA® to standard care in the context of a disease management program (DMP). RESULTS The study results show significant and clinically relevant reductions in HbA1c values of at least 0.4% in ESYSTA® users after 6 months. After 12 months, users achieved on average a HbA1c reduction of approximately 0.7%. These reductions are more pronounced compared to the matched control group. CONCLUSIONS The present study shows the effectiveness of the digital health application ESYSTA®. Using a matched control group further increased the internal and external validity of study results.

show abstract

Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts

Cited by 2 publications

References 52 publications

The Role of Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes

The Role of Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes

Evaluation of a Digital Health Application for Diabetics under real world conditions: Superior Outcomes Compared to Standard Care in a Matched Case-Control Study (Preprint)

Contact Info

Product

Resources

About